Viridian Therapeutics, Inc./DE Other Finite-Lived Intangible Assets, Gross
Viridian Therapeutics, Inc./DE (VRDN) had Other Finite-Lived Intangible Assets, Gross of $10.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:OtherFiniteLivedIntangibleAssetsGross · last filed 2026-08-06
- 2026-06-30: Other Finite-Lived Intangible Assets, Gross $10.00M.
| Period end | Other Finite-Lived Intangible Assets, Gross |
|---|---|
| 2026-06-30 | $10.00M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |